Captor Therapeutics ®
News
May 05, 2022
Captor Therapeutics to host R&D Day on May 18, 2022
May 02, 2022
Captor Therapeutics has released its 2021 report. Recent quarterly results have seen significant R&D progress; The Company has sufficient funds for further research and is meeting expenditures on schedule
April 20, 2022
Captor Therapeutics announces further robust in-vivo efficacy data from CT-01 TPD candidates for hepatocellular carcinoma
April 11, 2022
Captor Therapeutics announces molecular targets of CT-01 program developing TPD therapy for hepatocellular carcinoma
April 11, 2022
Captor Therapeutics invited to TPD panel at the 8th Annual LSX World Congress 2022
March 23, 2022
Captor Therapeutics named as the most innovative company on the WSE in the Stock Exchange Company of the Year ranking
March 18, 2022
Captor Therapeutics to Present at the 2nd Annual Targeted Protein Degradation Europe Summit 2022
February 25, 2022
Captor Therapeutics announces positive proof-of-concept efficacy in-vivo data for its lead CT-03 program with strong antitumor activity at all doses tested